143 results
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
," "encouraged," “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify
8-K
ld3c67bd
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
s9ogk7xcl9h
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
EX-99.1
t4zbeb6pp3tuq ecr
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.1
mx0xuiett0gbmjv3o
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-99.1
fumcszta0zq c6ux
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
EX-99.1
owmecfobotk s8z3c0es
16 Dec 22
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
8:17am
8-K
EX-99.1
8axywn1cqj9nv25k
28 Oct 22
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
5:18pm
8-K
EX-10.1
bpydagr3q
1 Aug 22
Departure of Directors or Certain Officers
5:10pm
8-K
EX-99.1
fp6o21
10 May 22
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
4:01pm
8-K
EX-10.2
xddf16
24 Feb 22
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
7:00am
8-K
9oc5gafrd4hgnsnlfl
24 Feb 22
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
7:00am